Cell Therapy Catapult Awards Major Contract to Cellular Therapeutics Limited to Accelerate WT1 Clinical Programme

The Cell Therapy Catapult has awarded a manufacturing contract to Manchester-based company, Cellular Therapeutics Limited (CTL), to accelerate its clinical programme to develop an engineered T cell treatment for blood cancers such as acute myeloid leukaemia and myelodysplastic syndrome.

The contract will run for the next 2-3 years, supporting the current Phase I and II trials which involves the genetic modification of the patient’s own T cells, so that they may recognise and destroy WT1-expressing cancer cells when infused back into the body.

CTL was selected through a rigorous qualification, tender and evaluation process which demonstrated the strength and depth of expertise available in the UK, and it complements the work carried out in collaboration with Imperial College London, University College London and Great Ormond Street Hospital, with scientists led by Prof Hans Stauss and Dr Emma Morris, and originally funded by the charity Leukaemia & Lymphoma Research.

Demand for immune cell therapy manufacturing is rapidly expanding globally and this contract puts CTL in a strong position to win more business and bring more cell and gene therapy investment to the UK. This complements the Cell Therapy Catapult’s £55 million large-scale GMP cell therapy manufacturing centre intended for late-stage trials and full commercialisation which is due to open in 2017.

Keith Thompson, CEO of the Cell Therapy Catapult, said: “This contract will greatly enhance our WT1 clinical programme and accelerate this research intended to benefit patients with these life-threatening disorders. We were looking for a company with the depth of expertise needed to manufacture a novel immune cell therapy and we were impressed by Professor Robert Hawkins and the team at Cellular Therapeutics.”

Professor Robert Hawkins, CEO of Cellular Therapeutics Ltd, said: “Cellular Therapeutics Ltd is delighted to be working with the Cell Therapy Catapult to manufacture cells for patients in this ground breaking trial. In the growing field of immuno-oncology, CTL is at the forefront of cell therapy manufacturing in Europe having a wealth of T cell therapy manufacturing and clinical trial experience built over many years in collaboration with the Christie Hospital and University of Manchester. Importantly, this contract will also help us obtain further manufacturing contracts and develop our business including our own cancer cell therapy products based on tumour infiltrating lymphocytes.”

Further Information on the WT1 programme is available here and details on Cellular Therapeutics Ltd here.